US equities |
META $623.96 ▼-1.05% TSLA $406.50 ▲+3.80% MU $932.91 ▲+3.23% NVDA $217.85 ▲+0.86% SPCX $150.14 ▲+2.21% AMD $559.51 ▲+5.31% SNDK $1,306.40 ▲+4.05% INTC $93.76 ▲+3.64%
FinancialContent

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

3.180 +0.260 (+8.90%)
Delayed Quote Updated: 12:59 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
News headline image
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Via ACCESS Newswire
News headline image
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Via ACCESS Newswire
News headline image
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Via ACCESS Newswire
News headline image
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
Via ACCESS Newswire
News headline image
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Via ACCESS Newswire
News headline image
Lexaria Releases Annual Letter from the CEO
Via ACCESS Newswire
News headline image
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
Via ACCESSWIRE
News headline image
Lexaria Bioscience Earnings Analysis: Q1 Recap ↗
 
Via Benzinga
News headline image
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Via ACCESSWIRE
News headline image
Lexaria Forms New Scientific Advisory Board
Via ACCESSWIRE
News headline image
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Via ACCESSWIRE
News headline image
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
Via ACCESSWIRE
News headline image
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Via ACCESSWIRE
News headline image
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
Via ACCESSWIRE
News headline image
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
Via ACCESSWIRE
News headline image
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
Via ACCESSWIRE
News headline image
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
Via ACCESSWIRE
News headline image
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Via ACCESSWIRE
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups 
Via TheNewswire.com
News headline image
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups 
Via TheNewswire.com
News headline image
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
News headline image
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
Via ACCESSWIRE
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Kelowna, British Columbia – October 16, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced... 
Via TheNewswire.com
Topics Regulatory Compliance
News headline image
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >